Cargando…
Hypogammaglobulinemia secondary to B-cell depleting therapies in neuroimmunology: Comparing management strategies
BACKGROUND: Anti-CD20 agents are commonly used in MS, NMOSD, and MOGAD. Few studies have compared strategies to address hypogammaglobulinemia. OBJECTIVE: To compare strategies to manage secondary hypogammaglobulinemia in neuroimmunology patients, including reducing anti-CD20 dose and dosing frequenc...
Autores principales: | Kelly, Hannah, Vishnevetsky, Anastasia, Chibnik, Lori B., Levy, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291859/ https://www.ncbi.nlm.nih.gov/pubmed/37377746 http://dx.doi.org/10.1177/20552173231182534 |
Ejemplares similares
-
Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia
por: Compagno, Nicolò, et al.
Publicado: (2014) -
Is Rituximab-Associated Hypogammaglobulinemia Always Linked to B-Cell Depletion?
por: Damianaki, Anthie, et al.
Publicado: (2022) -
Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders
por: Lehmann-Horn, Klaus, et al.
Publicado: (2011) -
B Cell Depletion and SARS‐CoV‐2 Vaccine Responses in Neuroimmunologic Patients
por: Kornek, Barbara, et al.
Publicado: (2022) -
Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications
por: Konen, Franz Felix, et al.
Publicado: (2022)